Does EoE Increase Risk of Esophageal Cancer?
No, eosinophilic esophagitis (EoE) does not increase the risk of esophageal cancer. Multiple guidelines and recent high-quality studies consistently demonstrate no association between EoE and esophageal malignancy.
Evidence from Guidelines
The most authoritative guideline evidence comes from the 2007 Gastroenterology consensus statement, which explicitly states: "EE has not been associated with the development of esophageal malignancy, although follow-up has been short" 111111. This guideline acknowledges that while chronic esophageal inflammation from acid reflux (GERD) contributes to Barrett's esophagus and potential esophageal cancer, the same concern does not apply to EoE 111.
The 2022 British Society of Gastroenterology guidelines 2 and 2020 AGA guidelines 3 do not identify esophageal cancer risk as a concern in EoE management, focusing instead on preventing esophageal dysfunction and strictures.
Recent High-Quality Research Evidence
The most recent and highest quality study is a 2025 case-control analysis using the MarketScan database 4. Among 5,562 esophageal cancer cases and 55,620 matched controls:
- Only 2 cancer cases (0.04%) had EoE versus 44 controls (0.08%)
- Odds ratio: 0.46 (95% CI 0.11-1.88) - suggesting no increased risk
- The co-incidence of EoE and esophageal cancer was extremely rare
A second 2025 study 5 examined 2,947,003 patients undergoing endoscopy and found:
- Incident esophageal cancer occurred in 0.06% of EoE patients versus 0.05% without EoE (p=0.36)
- No statistically significant difference in cancer risk
- The study concluded that "EoE is not associated with an increased risk of BE/EC"
Supporting Evidence
A 2024 Swedish nationwide cohort study 6 followed 1,580 EoE patients over median 7 years:
- Overall cancer risk was not increased (aHR 1.11; 95% CI 0.80-1.53)
- While 2 EoE patients developed esophageal cancer versus 1 reference individual, this was extremely rare with wide confidence intervals
- The authors urged caution with generalization given the small numbers
A 2017 cross-sectional study 7 of 27 million subjects found zero cases of esophageal cancer among EoE patients (p=0.575 for difference versus controls).
Mechanistic Insights
Emerging research 8 suggests that EoE-associated epithelial remodeling may actually limit esophageal carcinogenesis. The inflammatory changes in EoE appear fundamentally different from those in GERD-related Barrett's esophagus, with distinct cellular populations and gene expression patterns that do not promote malignant transformation.
Clinical Implications
- Surveillance for esophageal cancer is not indicated in EoE patients based solely on their EoE diagnosis
- The primary monitoring goals in EoE are preventing esophageal dysfunction, detecting strictures, and assessing treatment response 11
- Standard Barrett's esophagus screening strategies apply to EoE patients based on conventional risk factors (age, male sex, GERD, hiatal hernia), not because of their EoE 5
Important Caveats
- Most follow-up data span less than 10-15 years; ultra-long-term risk (>20-30 years) remains incompletely characterized
- The natural history of untreated EoE is still being defined 11
- While cancer risk is not increased, untreated EoE can lead to fibrostenotic complications (rings, strictures, narrowing) that significantly impact quality of life
You can reassure patients that EoE does not increase their esophageal cancer risk, but emphasize the importance of treatment to prevent structural complications and maintain quality of life.